AustriaAustria

Intercell AG to cut 50% cost after termination of Phase II/III trial of Staphylococcus aureus vaccine

09.06.2011

Vienna – Austrian Intercell AG has lost its partner Merck & Co after termination of a Phase II/III trial with Intercell’s vaccine candidate V710 against Staphylococcus aureus, the most frequent cause of hospital-acquired infections. According to the independent Data Monitoring Committee analyses of the proof-of-concept study, V710 was unlikely to demonstrate statistically significant clinical benefit. Additionally, there were safety concerns due to higher overall mortality and multi-organ dysfunction events in the vaccine group, compared to placebo recipients. Shares of Intercell dropped by 25% after the announcement. At the end of May, Intercell had to recall 5,000 of its marketed vaccine Ixiaro against Japanese Encephalitis. By December, the company had terminated development of its vaccine patch in traveller’s diarrhoea due to efficacy problems. In a press conference, the company’s new CEO Thomas Lingelbach, who replaces Gerd Zettlmeisl explained that the company will refocus on its products under clinical development and will reduce its expenses by 50%, particularly in R&D. Together with jobs cuts by 15% compared to 2010 numbers, the company hopes to reduce losses in the next 4 years.

AustriaAustria

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

AustriaAustria

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

AustriaAustria

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...

AustriaAustria

08.11.2011

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

AustriaAustria

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...

AustriaAustria

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

28.04.2011

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/article/intercell-ag-to-cut-50-cost-after-termination-of-phase-iiiii-trial-of-staphylococcus-aureus-vaccin.html

Product of the week

Products

Events

All Events

Current issue

All issues